Structure-activity relationship of novel DAPK inhibitors identified by structure-based virtual screening
- Bioorg Med Chem. 2010 Apr 1;18(7):2728-34. doi: 10.1016/j.bmc.2010.02.018.
- 1. Drug Discovery Department, Research & Development Division, PharmaDesign, Inc., 2-19-8 Hatchobori, Chuo-ku, Tokyo 104-0032, Japan. [email protected]
Death-associated protein kinase (DAPK) is a serine/threonine protein kinase implicated in diverse programmed cell death pathways. DAPK is a promising target protein for the treatment of ischemic diseases. We identified novel potent and selective DAPK inhibitors efficiently by structure-based virtual screening, then further developed the hit compounds. In this paper, we describe the development of the hit compounds and the structure-activity relationship studies of the DAPK inhibitors in detail, including calculation of the solvated interaction energy (SIE), and verification of selectivity using a kinase panel.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: DAPKResearch Areas: Cardiovascular Disease